Kraig Biocraft Laboratories, Inc. (OTCBB: KBLB)

Kraig Biocraft Laboratories, Inc. (OTCBB: KBLB) announced the availability of a new research report on Kraig and its Spider Silk.  

Breaking *NEWS* From Kraig Biocraft Labs

Press Release Source: Kraig Biocraft Laboratories, Inc.
Thursday July 24, 6:00 am ET

LANSING, Mich., July 24, 2008 (PRIME NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTC BB:KBLB.OB - News) announced today the availability of a new research report on the viability of the production of commercial quantities of spider silk and on Kraig Biocraft's role relative to the development of this technology. The report, issued by Emerging Growth Research, LLP provides an overview of the company, its technologies, and a background on the markets the company seeks to address.

The author of the report, Joseph Noel, Principal Analyst at Emerging Growth Research commented, ``Kraig Biocraft has assembled a team of top genetic scientists to create transgenic technologies for the production of spider silk. Science has been attempting to artificially create spider silk for many years with only very limited success. We believe the approach being pursued by Kraig, which utilizes some of the most advanced genetic techniques available today, is very sound. We will be monitoring the situation closely as we are expecting a breakthrough this Fall as the microinjection efforts heat up at the university labs associated with the company. This is truly groundbreaking genetic research potentially worth hundreds of million of dollars.''

``Spider silk is an incredible material and one of the strongest and most resilient known to mankind. Pound for pound, it is significantly stronger than steel, and its ability to absorb energy before breaking is unmatched,'' commented Kraig Biocraft's Chief Executive Officer, Kim K. Thompson. ``We believe that a significantly sized market exists for this material, and everyone associated with Kraig Biocraft Laboratories is working diligently to deliver this revolutionary fiber to the marketplace. We are excited to have this report available to the press, our investors, and to the marketplace in general, as we believe it makes a very complex technical subject easy to understand.''

The report is available for free download at: http://www.kraiglabs.com/pdf/KBLBReport.pdf

And alternatively at: http://www.scribd.com/doc/4012223/KBLB-Analyst-ReportJuly-2008

Kraig Biocraft Laboratories is a technology company focused on the development of commercially significant high-performance polymers, textile fibers and diverse platform technologies. Based on proprietary genetic engineering technology, Kraig is working to develop and produce polymers and protein-based materials including spider silk for use in the multibillion-dollar technical fibers market. For more information on Kraig Biocraft Laboratories and to hear an audio interview with Kraig's CEO, please visit the Company's website at http://www.KraigLabs.com.

The Kraig Biocraft Laboratories, Inc. logo is available at http://www.primenewswire.com/newsroom/prs/?pkgid=4817

About Emerging Growth Research, LLP
Emerging Growth Research, LLP operates as an independent research boutique. The Kraig Biocraft Laboratories report was produced by analyst Joseph Noel. Mr. Noel has been an analyst involved in growth companies for over 20 years and has extensive additional experience within the health care, biotech and technology sectors. Please reference the appropriate disclosures outlined in the report.

Statements in this press release about the company's future and expectations other than historical facts are ``forward-looking statements.'' These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as ``anticipates,'' ``foresees,'' ``hopes,'' ``develops,'' ``researching,'' ``research,'' ``could,'' ``expecting,'' ``potentially'' or other words or phrases of similar import. Similarly, statements in this release that describe the Company's or any analyst's outlook, objectives, plans, intentions, expectations, goals or business strategy should all be considered forward-looking statements. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements.

Contact:

          Kraig Biocraft Laboratories, Inc.
          Kim Thompson
          info@KraigLabs.com

          Emerging Growth Research, LLP
          Joseph Noel
          (925) 922-2560
<<<spacer>>>

About Kraig Biocraft Labs

Kraig Biocraft Laboratories, Inc. ("Kraig""KBLB") is a biotechnology company focused on the development of commercially significant high performance polymers and technical fiber. Based on proprietary genetic engineering technology, Kraig is working to develop and produce polymers and protein-based materials including Spider Silk. The company believes that Spider Silk is a “super fiber” that will have numerous commercial and consumer applications. 

High performance technical fibers are currently used in a wide variety of military, industrial, and consumer applications requiring superior strength, toughness and flexibility. Kraig investments in genetic research are focused on product development and innovative near term solutions to meet the practical problems of our world. Kraig is sponsoring genetic research at laboratories within the University of Notre Dame to create new polymers for the broad commercial markets that have been waiting for the next evolution of materials. Kraig has also been working with leading universities in the fields of genetics and genetic engineering to develop new varieties of recombinant fibers including spider silks and spider silk analogs.

Kraig has obtained the exclusive right, in its field of research, for the spider silk gene sequences which are at the core of its technology. These genetic sequences were first studied and subsequently patented by Dr. Randy Lewis of the University of Wyoming (Dr. Lewis is a KBLB scientific adviser).  In early 2006, Kraig obtained certain exclusive rights from the University of Wyoming to utilize the spider silk DNA sequences in its field of use.

Genetic Engineering is the means by which KBLB can manipulate DNA to modify and create new biochemical products. At Kraig, the trademark saying is  "The future is made in the laboratory" and that's more than a slogan. It is the company's future, and that of the next generation of materials science that KBLB is making with those genetic sequences. Management at KBLB is focused on the development of high strength materials and industrial polymers by working through collaborative research and licensing agreements in the field of genetics, with leading university laboratories. 

What's So Special About Spider Silk?

Spider Silk is among the strongest fibers produced in nature. Some spider species are capable of producing up to seven different types of silk depending upon the spider's particular need at that time. For example, a spider will use one type of silk to make the structural supports for it web, and another type to wrap its captured pray. Drag line silk, the silk used when a spider is repelling, is of particular commercial interest. This natural polymer is both extremely strong and extremely flexible.

However, spider silk is much less dense than steel; its tensile strength to density ratio is roughly five times higher than that of steel (i.e. it is five times as strong as steel of the same density — as strong as Aramid filaments, such as Twaron or Kevlar.)  In fact, a strand of spider silk long enough to circle the earth would weigh less than 16 ounces (450 g).

• Dragline silk: Used for the web's outer rim and spokes, as well as for the lifeline. As strong as steel, but much tougher. 
• Capture-spiral silk: Used for the capturing lines of the web. Sticky, extremely stretchy and tough. 
• Tubiliform silk: Used for protective egg sacs.  Stiffest silk. 
• Aciniform silk: Used to wrap and secure freshly captured prey. Two to three times as tough as the other silks. 
• Minor-ampullate silk: Used for minor, all-purpose applications.

Depending on the species, spiders will have anything from two to eight spinnerets, usually in pairs. The beginning of the gland is rich in thiol and tyrosine groups. After this beginning process, the ampulla acts as a storage sac for the newly created fibers. From there, the spinning duct effectively removes water from the fiber and through fine channels also assists in its formation. Lipid secretions take place just at the end of the distal limb of the duct, and proceeds to the valve. The valve is believed to assist in rejoining broken fibers, acting much in the way of a helical pump.

Unspun silk dope is pulled through silk glands, resulting in a transition from stored gel to final solid fiber. Many species of spider have different glands for different jobs, such as housing and web construction, defense, capturing and detaining prey, mobility and in extreme cases even as food. Thus, different specialized silks have evolved with material properties optimized for their intended use.
<<<Spacer>>>

The Market and the Applications

The DNA research that has been conducted in laboratories around the world over the last 20 years, has paved the way for new products and opened up commercial opportunities that would have been undreamed of a generation ago. DNA instructs cells in their life processes. Genetic engineering is the means by which that machinery is employed.

Artist Kebes using vector drawing software Structure of spider silk. Inside a typical fiber, one finds crystalline regions separated by amorphous linkages. The crystals are beta-sheets that have assembled together.

Transgenics is the scientific process of decoding the genetic instructions of an organism and applying those instructions to another organism. In that way, bio chemicals and other products can be produced and delivered on an industrial scale. KBLB is at the forefront of the coming revolution in materials technology.

Other Recent News From KBLB

Press Release Source: Kraig Biocraft Laboratories, Inc.
Wednesday June 4, 6:00 am ET

LANSING, Mich., June 4, 2008 (PRIME NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTC BB:KBLB.OB - News) announced today that Dr. Donald Jarvis of the University of Wyoming has entered into a formal consulting relationship with the Company. Earlier this year Dr. Jarvis joined Kraig's Board of Scientific Advisors. Dr. Jarvis's appointment to the advisory board was made in anticipation of his entering into this consulting agreement. Dr. Jarvis will retain his position on the advisory board.

Dr. Jarvis is currently conducting work at the University of Wyoming in the development of spider silk polymers. ``We view Dr. Jarvis's cutting edge work with protein expression systems and spider silk polymers as a great complement to Kraig's high strength polymers program,'' said Kraig's CEO Kim K. Thompson. ``The synergy created by the addition of Dr. Jarvis to our team puts us in a strong position in regard to both product and intellectual property development.''

Dr. Jarvis is a renowned inventor and the developer of technologies related to pharmaceutical platforms. It was his developmental work with spider silk polymers which first caught the attention of Kraig's CEO. Dr. Jarvis is very well known in the scientific community for his revolutionary work in genetics and biochemicals. The Consulting agreement announced today is subject to review by the University of Wyoming, however neither Kraig nor Dr. Jarvis anticipate any major difficulty in that area. Dr. Jarvis is the inventor or co-inventor of more than a dozen patent applications, including technologies related to pharmaceutical production. MORE

Press Release Source: Kraig Biocraft Laboratories, Inc.
Tuesday May 20, 6:00 am ET

LANSING, Mich., May 20, 2008 (PRIME NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTC BB:KBLB.OB - News) announced today that a leading university laboratory, working pursuant to Kraig's collaborative and sponsored research program, has mapped out the DNA sequence for a new enzyme. The new enzyme is being developed as an important part of the laboratories' work with Kraig in developing new high strength polymers based on spider silk. The enzyme will be used to cleave targeted DNA sequences so as to facilitate genetic manipulation for polymer synthesis.

"We have designed the enzyme specifically to accelerate our work on spider silk polymers,'' said Dr. Malcolm Fraser, who is the head of the University of Notre Dame research laboratory conducting this work. ``The enzyme should be ready for in vitro testing this summer. Because the enzyme is site specific, it will only cleave our targeted DNA at the precise target point. It is the biochemical equivalent of a rifle shot.''

The development of the enzyme fulfills an important part of the Company's collaborative research plan with the University. ``This success is rightly credited to Dr. Fraser and his team,'' said Kraig's CEO Kim Thompson. ``With the mapping of this DNA sequence our development program has taken another big leap forward. The benefit to Kraig's work on spider silk polymers is immeasurable. We believe that this exciting finding will play an important role in the development of high strength polymers and platform technologies.''

Kraig Biocraft Laboratories is a technology company focused on the development of commercially significant high-performance polymers, technical fibers and diverse platform technologies. Based on proprietary genetic engineering technology, Kraig is working to develop and produce polymers and protein-based materials including spider silk for use in the multi-billion dollar technical fibers market. MORE

Press Release Source: Kraig Biocraft Laboratories, Inc.
Thursday May 8, 6:00 am ET

LANSING, Mich., May 8, 2008 (PRIME NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTC BB:KBLB.OB - News) announced this morning that the Company has just signed a renewal and expansion of its Collaborative Research and Intellectual Property Agreement with the University of Notre Dame. The agreement provides Kraig with exclusive licensing rights for the products and technology developed pursuant to the collaboration. Additionally, the agreement extends and expands the Company's ongoing research and development program in the University's genetic laboratories.

"The sponsored research program with the University of Notre Dame is a continuing success,'' said Kraig's CEO Kim Thompson, "and has already resulted in two provisional patent filings. Kraig's renewal extends the collaborative research into 2009, and expands the focus of the Company's work to include the development of genetic expression systems. These recombinant DNA technologies have potential applications as pharmaceutical platforms and human diagnostics platforms. Each genetic expression system provides multiple possibilities for highly lucrative opportunities for the Company's technology."

The Company's primary focus will remain on the development of high performance, high tensile strength fibers for the multi-billion dollar technical textile market. However, the collaborative research agreement and university research plan will open up new opportunities for Kraig to develop pharmaceutical and diagnostic applications for its genetic engineering technology. This work will continue in the University under the direction of Dr. Malcolm Fraser, a renowned developer of genetic engineering technologies and a member of Kraig's board of scientific advisors.

Already in 2008, Kraig has been able to announce the filing of a provisional patent application for human diagnostic technologies. The invention was a byproduct of the Company's collaborative research program with the University. ``The new research plan announced today is an acknowledgement by the Company that this technology has broad applications as a platform technology. These platforms can potentially service multiple markets including human and animal diagnostics, pharmaceutical platforms and recombinant polymers,'' said Thompson.  MORE
aa

Financial Information for KBLB

Kraig Biocraft Laboratories, Inc. is represented by the law firm of: Anslow & Jaclin, LLP, 195 Route 9 South, Suite 204, Manalapan , NJ 07726. 
KBLB auditors are: Webb & Company, P.A., 1501 Corporate Drive, Suite 150, Boynton Beach , FL 33426. 
The KBLB transfer agent: Registrar & Transfer Company, 10 Commerce Drive, Cranford, NJ  07016-3572 - (800) 866-1340.
aa

TO CONTACT KBLB

Kraig Biocraft Laboratories, Inc.
Kim Thompson, CEO
120 North Washington Square, Suite 805, Lansing, Michigan 48933
Telephone: (517) 336-0807 - Email: corporate@KraigLabs.com
Web site: www.kraiglabs.com

120 N. Washington Sq.

---

*** The Bull is Running. ***
There may never be a better time to feature YOUR company
to over 1 MILLION investors.

To learn more about our programs email us directly at info@stockupticks.com

Disclaimer: StockUpTicks.com is a property of Market Pathways Financial Relations Incorporated (MP).  The information, opinions and analysis contained herein are based on third party sources believed to be reliable but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. Past performance is no guarantee of future results. This report is a paid advertisement and is for information purposes only and should not be used as the basis for any investment decision.  MP has been paid thirty thousand dollars by Kraig Biocraft Laboratories, Inc. for preparation and distribution of this report and other advertising services over a ninety day period. This constitutes a conflict of interest as to MP’s ability to remain objective in its communication regarding the subject company.  Write or call MP for detailed disclosure as required by Rule 17b of the Securities Act of 1933/1934 - Market Pathways 17595 Harvard Ave., Suite C519 Irvine, CA  92614.  MP is not an investment advisor and this report is not investment advice. This information is neither a solicitation to buy nor an offer to sell securities but is a paid advertisement.  Information contained herein contains forward-looking statements and is subject to significant risks and uncertainties, which will affect the results.  The opinions contained herein reflect our current judgment and are subject to change without notice. MP and/or its affiliates, associates and employees from time to time may have either a long or short position in securities mentioned.  Information contained herein may not be reproduced in whole or in part without the express written consent of Market Pathways Financial Relations Incorporated.